Management of adrenal insufficiency in different clinical settings

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 14, 2005, Pages 2407-2417

  Hahner, Stefanie ^a   Allolio, Bruno ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Addison's disease; Adrenal crisis; Adrenal insufficiency; Dehydroepiandosterone; Glucocorticoid mineralocorticoid replacement; Sepsis

Indexed keywords

AMINOGLUTETHIMIDE; CORTICOSTEROID; CORTISONE ACETATE; ETOMIDATE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; KETOCONAZOLE; MINERALOCORTICOID; MITOTANE; PHENOBARBITAL; PHENYTOIN; PRASTERONE; PREDNISONE; RIFAMPICIN; STEROID; THYROXINE;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; CANCER SURGERY; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG INDICATION; FATIGUE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS TUMOR; INFECTION; MOOD; PATIENT EDUCATION; PLASMA RENIN ACTIVITY; PREVALENCE; REVIEW; SEPSIS; SEXUALITY; STRESS; SURGERY; WELLBEING; WESTERN HEMISPHERE;

ACUTE DISEASE; ADRENAL INSUFFICIENCY; CLINICAL TRIALS; DEHYDROEPIANDROSTERONE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FLUDROCORTISONE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; MINERALOCORTICOIDS; PATIENT EDUCATION; PITUITARY GLAND; PREGNANCY; PREGNANCY COMPLICATIONS; SHOCK, SEPTIC; STRESS; SURGICAL PROCEDURES, OPERATIVE;

EID: 28244463447     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.14.2407     Document Type: Review

References (72)

1. SOULE S. Addison's disease in Africa - a teaching hospital experience. Clin. Endocrinol. (1999) 50:115-120.
2. LAM KY, LO CY. A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin. Endocrinol. (2001) 54:633-639.
3. BETTERLE C, DAL PRA C, MANTERO F, ZANCHETTA R. Autoimmune adrenal insufficiency and autoinumme polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. (2002) 23:327-364.
4. NEUFELD M, MACLAREN NK, BLIZZARD RM: Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (1981) 60:355-362.
5. ZELISSEN PM, BAST EJ, CROUGHS RJ: Associated autoimmunity in Addison's disease. J. Autoimmun. (1995) 8:121-130.
6. LAURETI S, VECCHI L, SANTEUSANIO F, FALORNI A: Is the prevalence of Addison's disease underestimated? J. Clin. Endocrinol. Metab. (1999) 84:1762.
7. LOVAS K, HUSEBYE ES: High prevalence and increasing incidence of Addison's disease in western Norway. Clin. Endocrinol. (2002) 56:787-791.
8. ESTEBAN NV, LOUGHLIN T, YERGEY AL et al.: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. (1991) 72:39-45.
9. KERRIGAN JR, VELDHUIS JD, LEYO SA, IRANMANESH A, ROGOL AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J. Clin. Endocrinol. Metab. (1993) 76:1505-1510.
10. KRAAN GP, DULLAART RP, PRATT JJ, WOLTHERS BG, DRAYER NM, DE BRUIN R: The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J. Clin. Endocrinol. Metab (1998) 83:1247-1252.
11. BRANDON DD, ISABELLE LM, SAMUELS MH, KENDALL JW, LORIAUX DL: Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids (1999) 64:372-378.
12. KEHLET H, BINDER C, BLICHERT-TOFT M: Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin. Endocrinol. (1976) 5:37-41.
13. ALLOLIO B, KAULEN D, DEUSS U, HIPP FX, WINKELMANN W: Comparison between hydrocortisone and cortisone acetate as replacement therapy in adrenocortical insufficiency. Akt. Endokr. Stoffw. (1985) 6:35-39.
14. OELKERS W, DIEDERICH S, BAHR V: Therapeutic strategies in adrenal insufficiency. Ann. Endocrinol. (2001) 62:212-216.
15. LAURETI S, FALORNI A, SANTEUSANIO F: Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J. Endocrinol. Invest. (2003) 26:1071-1075.
16. PEACEY SR, GUO CY, ROBINSON AM et al.: Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin. Endocrinol. (1997) 46:255-261.
17. HOWLETT TA: An assessment of optimal hydrocortisone replacement therapy. Clin. Endocrinol. (1997) 46:263-268.
18. MAH PM, JENKINS RC, ROSTAMI-HODJEGAN A et al: Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin. Endocrinol. (2004) 61:367-375.
19. FEEK CM, RATCLIFFE JG, SETH J, GRAY CE, TOFT AD, IRVINE WJ: Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin. Endocrinol. (1981) 14:451-458.
20. SCOTT RS, DONALD RA, ESPINER EA: Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin. Endocrinol. (1978) 9:571-576.
21. ARLT W, ROSENTHAL C, HAHNER S, ALLOLIO B: Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin. Endocrinol. (in press).
22. BURCH WM: Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. JAMA (1982) 247:2002-2004.
23. MONSON JP: The assessment of glucocorticoid replacement therapy. Clin. Endocrinol. (1997) 46:269-270.
24. AL-SHOUMER KA, BESHYAH SA, NITHTHYANANTHAN R, JOHNSTON DG: Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin. Endocrinol. (1995) 42:85-90.
25. ZELISSEN PM, CROUGHS RJ, VAN RIJK PP, RAYMAKERS JA: Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. (1994) 120:207-210.
26. FLORKOWSKI CM, HOLMES SJ, ELLIOT JR, DONALD RA, ESPINER EA: Bone mineral density is reduced in female but not male subjects with Addison's disease. N Z Med. J. (1994) 107:52-53.
27. OELKERS W, DIEDERICH S, BAHR V: Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J. Clin. Endocrinol. Metab. (1992) 75:259-264.
28. ARLT W, CALLIES F, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. (1999) 341:1013-1020.
29. HUNT PJ, GURNELL EM, HUPPERT FA et al.: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. (2000) 85:4650-4656.
30. JOHANNSSON G, BURMAN P, WIREN L et al.: Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab (2002) 87:2046-2052.
31. LOVAS K, LOGE JH, HUSEBYE ES: Subjective health status in Norwegian patients with Addison's disease. Clin. Endocrinol. (2002) 56:581-588.
32. ROSEN T, WIREN L, WILHELMSEN L, WIKLUND I, BENGTSSON BA: Decreased psychological well-being in adult patients with growth hormone deficiency. Clin. Endocrinol. (1994) 40:111-116.
33. SCHMIDT PJ, DALY RC, BLOCH M et al.: Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch. Gen. Psychiatry (2005) 62:154-162.
34. SULLIVAN SD, MOENTER SM: Neurosteroids alter gamma-aminobutyric acid postsynaptic currents in gonadotropin-releasing hormone neurons: a possible mechanism for direct steroidal control. Endocrinology (2003) 144:4366-4375.
35. LIU D, DILLON JS: Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J. Biol. Chem. (2002) 277:21379-21388.
36. REINCKE M, ALLOLIO B, WURTH G, WINKELMANN W: The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J. Clin. Endocrinol. Metab. (1993) 77:151-156.
37. BEISHUIZEN A, THIJS LG: Relative adrenal failure in intensive care: an identifiable problem requiring treatment? Best Pract. Res. Clin. Endocrinol. Metab. (2001) 15:513-531.
38. SALEM M, TAINSH RE JR, BROMBERG J, LORIAUX DL, CHERNOW B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann. Surg. (1994) 219:416-425.
39. GLOWNIAK JV, LORIAUX DL: A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery (1997) 121:123-129.
40. SYMRENG T, KARLBERG BE, KAGEDAL B, SCHILDT B: Physiological cortisol substitution of long-term steroid-treated patients undergoing major surgery. Br. J. Anaesth. (1981) 53:949-954.
41. NICHOLSON G, BURRIN JM, HALL GM: Peri-operative steroid supplementation. Anaesthesia (1998) 53:1091-1104.
42. UDELSMAN R, NORTON JA, JELENICH SE et al.: Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J. Clin. Endocrinol. Metab. (1987) 64:986-994.
43. DONALD RA, PERRY EG, WITTERT GA et al.: The plasma ACTH, AVP, CRH and catecholamine responses to conventional and laparoscopic cholecystectomy. Clin. Endocrinol. (1993) 38:609-615.
44. KLOSE M, JORGENSEN K, KRISTENSEN LO: Characteristics of recovery of adrenocortical function after treatment for Cushing's syndrome due to pituitary or adrenal adenomas. Clin. Endocrinol. (2004) 61:394-399.
45. INDER WJ, HUNT PJ: Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J. Clin. Endocrinol. Metab. (2002) 87:2745-2750.
46. COURTNEY CH, MCALLISTER AS, MCCANCE DR et al.: Comparison of one week 0900 h serum cortisol, low and standard dose synacthen tests with a 4 to 6 week insulin hypoglycaemia test after pituitary surgery in assessing HPA axis. Clin. Endocrinol. (2000) 53:431-436.
47. WATTS NB, TINDALL GT: Rapid assessment of corticotropin reserve after pituitary surgery. JAMA (1988) 259:708-711.
48. AUCHUS RJ, SHEWBRIDGE RK, SHEPHERD MD: Which patients benefit from provocative adrenal testing after transsphenoidal pituitary surgery? Clin. Endocrinol. (1997) 46:21-27.
49. LANGE M, SVENDSEN OL, SKAKKEBAEK NE et al.: An audit of the insulin-tolerance test in 255 patients with pituitary disease. Eur. J. Endocrinol. (2002) 147:41-47.
50. ARLT W, ALLOLIO B: Adrenal insufficiency. Lancet (2003) 361:1881-1893.
51. ALLOLIO B, HOFFMANN J, LINTON EA, WINKELMANN W, KUSCHE M, SCHULTE HM: Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone. Clin. Endocrinol. (1990) 33:279-289.
52. LINDSAY JR, NIEMAN LK: The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr. Rev. (2005) [Epub ahead of print].
53. DIEDERICH S, BAHR V, OELKERS W: Therapy of adrenal cortex insufficiency. Dtsch. Med. Wochenschr. (1994) 119:595-597.
54. SCHLAGHECKE R, KORNELY E, SANTEN RT, RIDDERSKAMP P: The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N. Engl. J. Med. (1992) 326:226-230.
55. LAROCHELLE GE JR, LAROCHELLE AG, RATNER RE, BORENSTEIN DG: Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am. J. Med. (1993) 95:258-264.
56. HENZEN C, SUTER A, LERCH E, URBINELLI R, SCHORNO XH, BRINER VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet (2000) 355:542-545.
57. DRUCKER D, MCLAUGHLIN J: Adrenocortical dysfunction in acute medical illness. Crit. Care Med. (1986) 14:789-791.
58. LAMBERTS SW, BRUINING HA, DE JONG FH: Corticosteroid therapy in severe illness. N. Engl. J. Med. (1997) 337:1285-1292.
59. CHERNOW B, ALEXANDER HR, SMALLRIDGE RC et al: Hormonal responses to graded surgical stress. Arch. Intern. Med. (1987) 147:1273-1278.
60. VERMES I, BEISHUIZEN A: The hypothalamic-pituitary-adrenal response to critical illness. Best Pract. Res. Clin. Endocrinol. Metab. (2001) 15:495-511.
61. JURNEY TH, COCKRELL JL JR, LINDBERG JS, LAMIELL JM, WADE CE: Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest (1987) 92:292-295.
62. FINDLING JW, WATERS VO, RAFF H: The dissociation of renin and aldosterone during critical illness. J. Clin. Endocrinol. Metab. (1987) 64:592-595.
63. BARTON RN, STONER HB, WATSON SM: Relationships among plasma cortisol, adrenocorticotrophin, and severity of injury in recently injured patients. J. Trauma (1987) 27:384-392.
64. SCHROEDER S, WICHERS M, KLINGMULLER D et al.: The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit. Care Med. (2001) 29:310-316.
65. ANNANE D, SEBILLE V, CHARPENTIER C et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 288:862-871.
66. ANNANE D, BELLISSANT E, BOLLAERT PE, BRIEGEL J, KEH D, KUPFER Y: Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. Br. Med. J. (2004) 329:480.
67. KEH D, BOEHNKE T, WEBER-CARTENS S et al.: Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med. (2003) 167:512-520.
68. COOPER MS, STEWART PM: Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. (2003) 348:727-734.
69. HAMRAHIAN AH, OSENI TS, ARAFAH BM: Measurements of serum free cortisol in critically ill patients. N. Engl. J. Med. (2004) 350:1629-1638.
70. MINNECI PC, DEANS KJ, BANKS SM, EICHACKER PQ, NATANSON C: Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann. Intern. Med. (2004) 141:47-56.
71. MARIK PE, ZALOGA GP: Adrenal insufficiency in the critically ill: a new look at an old problem. Chest (2002) 122:1784-1796.
72. HAGUE RV, MAY W, CULLEN DR: Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma. Clin. Endocrinol. (1989) 31:51-57.